title: Genistein decreases androgen biosynthesis in rat Leydig cells by interference with luteinizing hormone-dependent signaling.
abstract: Testicular Leydig cells express estrogen receptors and are the predominant source of the male sex steroid hormone testosterone (T). Previous studies demonstrated that genistein acts through estrogen receptors in Leydig cells. In the present study, pre-treatment of Leydig cells isolated from 35 day-old male Long Evans rats with the epidermal growth factor receptor (EGFR) kinase inhibitor AG 1478 abrogated genistein inhibition of T biosynthesis. Also, incubation of Leydig cells in culture medium containing epidermal growth factor (EGF) decreased T secretion (control: 255+/-16; EGF: 190+/-17ng/10(6) cells, 24h) (P<0.05). However, T secretion by genistein-treated Leydig cells (0.1nM, 10muM; 24h) was rescued by post-treatment incubation with forskolin (control: 275+/-28 versus 325+/-35; 780+/-85; ng/10(6) cells, 3h) and dibutyryl cyclic adenosine 3'-5'-monophosphate (dbcAMP) (control: 370+/-65 versus 580+/-75; 2500+/-200; ng/10(6) cells, 3h) (P>0.05). Furthermore, post-treatment incubation with cholera toxin, an activator of G proteins, caused genistein-treated Leydig cells to produce similar T amounts as untreated control (control: 55+/-5 versus 52+/-2 and 47+/-4; ng/10(6) cells, 3h) (P>0.05). These observations imply that genistein action interferes with coupling of transmembrane luteinizing hormone receptors (LHR) with G proteins. Uncoupling of LHR from G proteins adversely affects adenylate cyclase function and impacts LH-dependent stimulation of Leydig cells. These findings have implications for testicular steroidogenesis in individuals exposed to genistein and soy-based products.
authors.affiliation: Department of Anatomy, Physiology and Pharmacology, Auburn University, Auburn, AL 36849, United States.
authors.forename: Karen D
authors.initials: KD
authors.lastname: Hancock
authors.forename: Elaine S
authors.initials: ES
authors.lastname: Coleman
authors.forename: Ya-Xiong
authors.initials: YX
authors.lastname: Tao
authors.forename: Edward E
authors.initials: EE
authors.lastname: Morrison
authors.forename: Tim D
authors.initials: TD
authors.lastname: Braden
authors.forename: Barbara W
authors.initials: BW
authors.lastname: Kemppainen
authors.forename: Benson T
authors.initials: BT
authors.lastname: Akingbemi
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D002478:Cells, Cultured; D002772:Cholera Toxin / Q000494:pharmacology; D005576:Colforsin / Q000494:pharmacology; D003563:Cyclic CMP / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D052244:Endocrine Disruptors / Q000633:toxicity*; D020536:Enzyme Activators / Q000494:pharmacology; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors / Q000187:drug effects / Q000378:metabolism; D019833:Genistein / Q000633:toxicity*; D007985:Leydig Cells / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D007986:Luteinizing Hormone / Q000378:metabolism*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011799:Quinazolines; D051381:Rats; D020318:Rats, Long-Evans; D011974:Receptors, LH / Q000187:drug effects / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D013739:Testosterone / Q000096:biosynthesis*; D020032:Tyrphostins / Q000494:pharmacology
chemical_list: D052244:Endocrine Disruptors; D020536:Enzyme Activators; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D011974:Receptors, LH; D020032:Tyrphostins; C101044:RTKI cpd; D005576:Colforsin; D003563:Cyclic CMP; D013739:Testosterone; D004815:Epidermal Growth Factor; C053441:dibutyryl cyclic-3',5'-cytidine monophosphate; D007986:Luteinizing Hormone; D002772:Cholera Toxin; D019833:Genistein; C483803:Egfr protein, rat; D066246:ErbB Receptors; D000262:Adenylyl Cyclases